References
- Alberts SR, Sargent DJ, Nair S, et al. (2012). Effect of oxaliplatin, fluorouracil, and leucovorin with or without cetuximab on survival among patients with resected stage III colon cancer: a randomized trial. JAMA 307:1383–93
- Allen TM. (2002). Ligand-targeted therapeutics in anticancer therapy. Nat Rev Cancer 2:750–63
- Bagari R, Bansal D, Gulbake A, et al. (2011). Chondroitin sulfate functionalized liposomes for solid tumor targeting. J Drug Target 19:251–7
- Bangham AD, Standish MM, Watkins JC. (1965). Diffusion of univalent ions across the lamellae of swollen phospholipids. J Mol Biol 13:238–52
- Blum HE. (2005). Hepatocellular carcinoma: therapy and prevention. World J Gastroenterol 11:7391–440
- Culy CR, Clemett D, Wiseman LR. (2000). Oxaliplatin. A review of its pharmacological properties and clinical efficacy in metastatic colorectal cancer and its potential in other malignancies. Drugs 60:895–924
- de Lope CR, Tremosini S, Forner A, et al. Management of HCC (2012). J Hepatol 56:S75–87
- Elaine MM, Gary GL. (2008). Drug nanoparticles: formulating poorly water-soluble compounds. Toxicol Pathol 36:43–8
- Graham J, Mushin M, Kirkpatrick P. (2004). Oxaliplatin. Nat Rev Drug Discov 3:11–2
- Harper BW, Krause-Heuer AM, Grant MP, et al. (2010). Advances in platinum chemotherapeutics. Chemistry 25:7064–77
- Hashida M, Nishikawa M, Takakura Y. (1995). Hepatic targeting of drugs and proteins by chemical modification. J Control Release 36:99–107
- Honecker FU, Brümmendorf TH, Klein O, Bokemeyer C. (2006). Safe use of oxaliplatin in a patient with metastatic breast cancer and combined renal and hepatic failure. Onkologie 29:273–5
- Ma K, Shen H, Shen S, et al. (2011). Development of a successive targeting liposome with multi-ligand for efficient targeting gene delivery. J Gene Med 13:290–301
- Maruyama K, Holmberg E, Kennel SJ, et al. (1990). Characterization of in vivo immunoliposome targeting to pulmonary endothelium. J Pharm Sci 79:978–84
- Mishra B, Patel BB, Tiwari S. (2010). Colloidal nanocarriers: a review on formulation technology, types and applications toward targeted drug delivery. Nanomedicine 6:9–24
- Mishra PK, Gulbake A, Jain A, et al. (2009). Targeted delivery of an anti-cancer agent via steroid coupled liposomes. Drug Delivery 16:437–47
- Mosmann T. (1983). Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 65:55–63
- Muthu MS, Singh S. (2009). Targeted nanomedicines: effective treatment modalities for cancer, AIDS and brain disorders. Nanomedicine (Lond) 4:105–18
- Rensen PC, Sliedregt LA, Ferns M, et al. (2001). Determination of the upper size limit for uptake and processing of ligands by the asialoglycoprotein receptor on hepatocytes in vitro and in vivo. J Biol Chem 276:37577–84
- Sorensen EN, Weisman G, Vidaver GA. (1977). A sephadex column procedure for measuring uptake and loss of low molecular weight solutes from small, lipid-rich vesicles. Anal Biochem 82:376–84
- Torchilin VP. (2005). Recent advances with liposomes as pharmaceutical carriers. Nat Rev Drug Discov 4:145–60
- Wang SN, Deng YH, Xu H, et al. (2006). Synthesis of a novel galactosylated lipid and its application to the hepatocyte-selective targeting of liposomal doxorubicin. Eur J Pharm Biopharm 62:32–8
- Xiang Q, Zhang D, Wang J, et al. (2014). Cabozantinib reverses multidrug resistance of human hepatoma HepG2/adr cells by modulating the function of P-glycoprotein. Liver Int doi: 10.1111/liv.12524. [Epub ahead of print]
- Yen Y, Lim DW, Chung V, et al. (2008). Phase II study of oxaliplatin in patients with unresectable, metastatic, or recurrent hepatocellular cancer: a California Cancer Consortium Trial. Am J Clin Oncol 31:317–22